Spruce Biosciences, Inc. (SPRB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Spruce Biosciences, Inc. (SPRB) closed at USD 38.98 on 2026-10-14, a change of -68.7 % over the past year, with a market capitalization of USD 119.19M.

Spruce Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Spruce Biosciences, Inc. key figures

Previous close

USD 38.98 (2026-10-14)

1-year change

-68.7 %

Market cap

USD 119.19M

Enterprise value

USD 30.56M

P/E ratio (trailing)

-1.10

P/E ratio (forward)

8.34

EPS (trailing)

-37.86

EPS (forward)

4.98

PEG ratio

n/a

Price to book

1.36

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.02

Employees

22

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Spruce Biosciences, Inc. and compare it with other stocks.